Christian Schierholz

StratifAI is a precision oncology company developing the next generation of biomarkers to advance cancer diagnostics. Our discovery platform, Polaris™, applies multimodal AI to clinical data, identifying prognostic and predictive biomarkers that enable more equitable and individualized treatment strategies across solid-tumor cancers. Polaris™ Breast, the company’s first diagnostic, assesses metastatic risk in early breast cancer directly from digitized histology slides, supporting better treatment decisions. Retrospectively validated on thousands of patients from Phase III trials and real-world clinical settings, Polaris™ Breast is available for research use only and is undergoing regulatory approval in the EU and US.

100+ million people globally suffer from vision-threatening retinal diseases. A $13bn drug can stop patients from vision loss. Still, ⅔ of cases of blindness in EU+US are due to these diseases like wet AMD. We provide an AI-based precision health platform that emulates a proven clinical method. This method used 2nd expert opinion for eye doctors to achieve 6x(!) better therapy results across thousands of patients: - Improving real-world vision outcomes by 3x (36% > 100%) - Keeping 2x more patients in therapy (38% > 78%) Our big vision is to prevent 1 million additional people from blindness by 2030 by empowering ophthalmologists with AI-based optimal therapy prognosis. Our pre-clinical AI is used by pharma, payors and providers’ associations to gain new insights on their therapy data. We work on our clinical product to provide therapy decision support with 1 click at the PoC in 2024.

ETERNO is building the operating system for outpatient care in Europe - combining modern, physician-led clinics with a cloud-native, AI-powered healthcare platform. We replace fragmented legacy systems with a unified stack that automates care delivery, operations and economics at scale - empowering doctors, teams and patients to focus on what truly matters: better healthcare.

Fertilly is your partner for finding fertility centres in Europe. We are happy to advise you free of charge on the topics of fertility, IVF/ICSI and social freezing.

Biograil™ is a pre-clinical stage pharmaceutical company leveraging its proprietary BIONDD™ technology to unlock the potential of transforming the tremendous market of injectable pharmaceutical products into convenient oral capsules. We strive to make the most effective and convenient pharmaceuticals to patients in innovative and prioprietary ways by combining known technologies.

OnDosis Dosage Manager delivers flexible and individualized dosing of oral medicines formulated as pellets, granules, mini tablets or powders. We are writing a new chapter in personalized medicine, and enable closed loop disease management. OnDosis is currently developing products for individualized dosing in diseases with a significant burden on patients and healthcare such as ADHD, pain management and immunosuppression for organ transplants. Hundreds of thousands of patients with these conditions could be helped by improved dosing, ultimately leading to improving health care outcomes. OnDosis was founded as a spin-out from AstraZeneca in 2017 and is headquartered in Gothenburg, Sweden.

VisionHealth develops and implements innovative digital healthcare solutions at the highest level, enabling real progress and improvement of therapy standards for patients in a networked world. The pioneers in the field of digital respiratory treatments bring together excellence in the areas of respiratory therapy, digitalization, regulations and marketing to create unique interdisciplinary, international expertise. The German start-up company makes use of an excellent infrastructure and direct links to universities and experts. The managing directors are recognized specialists in pneumology and respiration and have many years of outstanding experience in their fields. The dynamic team has made a name for itself in respiratory medicine, IT and the market. https://visionhealth.gmbh/impressum/

Nutrient imbalance is the #1 health risk in the Western world. Baze has developed the first personalized nutrient supplement service to address this. Pioneering a dynamic data-driven approach based on recurring comfortable blood analysis.

Amiko provides Respiro, a digital medicine platform for use with connected inhalers that combines data, artificial intelligence, and elegant digital experiences to upgrade respiratory care.

StratifAI is a precision oncology company developing the next generation of biomarkers to advance cancer diagnostics. Our discovery platform, Polaris™, applies multimodal AI to clinical data, identifying prognostic and predictive biomarkers that enable more equitable and individualized treatment strategies across solid-tumor cancers. Polaris™ Breast, the company’s first diagnostic, assesses metastatic risk in early breast cancer directly from digitized histology slides, supporting better treatment decisions. Retrospectively validated on thousands of patients from Phase III trials and real-world clinical settings, Polaris™ Breast is available for research use only and is undergoing regulatory approval in the EU and US.

100+ million people globally suffer from vision-threatening retinal diseases. A $13bn drug can stop patients from vision loss. Still, ⅔ of cases of blindness in EU+US are due to these diseases like wet AMD. We provide an AI-based precision health platform that emulates a proven clinical method. This method used 2nd expert opinion for eye doctors to achieve 6x(!) better therapy results across thousands of patients: - Improving real-world vision outcomes by 3x (36% > 100%) - Keeping 2x more patients in therapy (38% > 78%) Our big vision is to prevent 1 million additional people from blindness by 2030 by empowering ophthalmologists with AI-based optimal therapy prognosis. Our pre-clinical AI is used by pharma, payors and providers’ associations to gain new insights on their therapy data. We work on our clinical product to provide therapy decision support with 1 click at the PoC in 2024.

ETERNO is building the operating system for outpatient care in Europe - combining modern, physician-led clinics with a cloud-native, AI-powered healthcare platform. We replace fragmented legacy systems with a unified stack that automates care delivery, operations and economics at scale - empowering doctors, teams and patients to focus on what truly matters: better healthcare.

Arve Capital is the venture capital arm of the Sanner Family Office with an investment focus on early-stage technology companies in the area of health and well-being. Based on the entrepreneurial roots in the healthcare sector, Arve Capital is a dedicated long-term partner for passionate founders on their mission to ensure and promote healthy lives.

Fertilly is your partner for finding fertility centres in Europe. We are happy to advise you free of charge on the topics of fertility, IVF/ICSI and social freezing.